Bone Biologics Corp
BBLGW9.000USD
-8.640-48.98%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Bone Biologics Corp Company
Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Bone Biologics Corp Info
Ticker SymbolBBLGW
Company nameBone Biologics Corp
IPO dateNov 27, 2015
CEOMr. Jeffrey Frelick
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address2 Burlington Woods Dr Ste 100
CityBURLINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01803-4551
Phone17815524452
Websitehttps://www.bonebiologics.com/
Ticker SymbolBBLGW
IPO dateNov 27, 2015
CEOMr. Jeffrey Frelick
Company Executives of Bone Biologics Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 18
Updated: Sun, May 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
4
35.82K
0.00%
--
2025Q3
5
35.82K
0.00%
-100.00
2025Q2
5
35.92K
0.00%
-3.00
2025Q1
8
35.92K
0.00%
-171.00K
2024Q4
8
34.80K
0.00%
-2.00K
2024Q3
8
36.79K
0.00%
+24.00
2024Q2
9
177.24K
0.00%
+3.53K
2024Q1
9
173.71K
0.00%
-138.84K
2023Q4
8
140.47K
0.00%
-24.39K
2023Q3
8
164.86K
0.00%
+23.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citadel Advisors LLC
35.67K
0%
-3.00
-0.01%
Jun 30, 2025
UBS Financial Services, Inc.
143.00
0%
--
--
Jun 30, 2025
BofA Global Research (US)
100.00
0%
--
--
Jun 30, 2025
Clear Street LLC
--
0%
-100.00
-100.00%
Jun 30, 2024
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Bone Biologics Corp?
The top five shareholders of Bone Biologics Corp are:
Citadel Advisors LLC holds 35.67K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 143.00 shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 100.00 shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 35.67K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 143.00 shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 100.00 shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Bone Biologics Corp?
The top three shareholder types of Bone Biologics Corp are:
Other
Other
How many institutions hold shares of Bone Biologics Corp (BBLGW)?
As of 2025Q4, 4 institutions hold shares of Bone Biologics Corp, with a combined market value of approximately 35.82K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Bone Biologics Corp?
In --, the -- business generated the highest revenue for Bone Biologics Corp, amounting to -- and accounting for --% of total revenue.
